Search research articles
Contact Us
Filters
Showing results (131-140 of 143) with videos related to
Page
of 15
Sort By:
Anticancer Research
|
May 6, 2020
Recombinant Methioninase Combined With Tumor-targeting <i>Salmonella typhimurium</i> A1-R Induced Regression in a PDOX Mouse Model of Doxorubicin-resistant Dedifferentiated Liposarcoma
Kentaro Igarashi, Kei Kawaguchi, Ming Zhao, et al.
Anticancer Research
|
September 15, 2019
Oral Recombinant Methioninase, Combined With Oral Caffeine and Injected Cisplatinum, Overcome Cisplatinum-Resistance and Regresses Patient-derived Orthotopic Xenograft Model of Osteosarcoma
Takashi Higuchi, Hiromichi Oshiro, Kentaro Miyake, et al.
Cell Cycle (Georgetown, Tex.)
|
December 1, 2017
Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and prevention
Kei Kawaguchi, Qinghong Han, Shukuan Li, et al.
Oncotarget
|
March 16, 2018
Intra-tumor L-methionine level highly correlates with tumor size in both pancreatic cancer and melanoma patient-derived orthotopic xenograft (PDOX) nude-mouse models
Kei Kawaguchi, Qinghong Han, Shukuan Li, et al.
Anticancer Research
|
October 3, 2018
Oral Recombinant Methioninase Combined with Caffeine and Doxorubicin Induced Regression of a Doxorubicin-resistant Synovial Sarcoma in a PDOX Mouse Model
Takashi Higuchi, Kei Kawaguchi, Kentaro Miyake, et al.
Anticancer Research
|
September 15, 2019
Oral Recombinant Methioninase Overcomes Colorectal-cancer Liver Metastasis Resistance to the Combination of 5-Fluorouracil and Oxaliplatinum in a Patient-derived Orthotopic Xenograft Mouse Model
Hiromichi Oshiro, Yasunori Tome, Tasuku Kiyuna, et al.
Oncotarget
|
April 14, 2017
Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model
Takashi Murakami, Shukuan Li, Qinghong Han, et al.
Journal of Cellular Biochemistry
|
November 17, 2017
Growth of doxorubicin-resistant undifferentiated spindle-cell sarcoma PDOX is arrested by metabolic targeting with recombinant methioninase
Kentaro Igarashi, Shukuan Li, Qinghong Han, et al.
Chemotherapy
|
January 24, 2019
Combining Tumor-Selective Bacterial Therapy with Salmonella typhimurium A1-R and Cancer Metabolism Targeting with Oral Recombinant Methioninase Regressed an Ewing's Sarcoma in a Patient-Derived Orthotopic Xenograft Model
Kentaro Miyake, Tasuku Kiyuna, Shukuan Li, et al.
Oncotarget
|
May 4, 2018
Recombinant methioninase combined with doxorubicin (DOX) regresses a DOX-resistant synovial sarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model
Kentaro Igarashi, Kei Kawaguchi, Shukuan Li, et al.
Page
of 15
Search research articles
Search
Showing results (131-140 of 143) with videos related to
Sort By:
Page
of 15
Anticancer Research
|
May 6, 2020
Recombinant Methioninase Combined With Tumor-targeting <i>Salmonella typhimurium</i> A1-R Induced Regression in a PDOX Mouse Model of Doxorubicin-resistant Dedifferentiated Liposarcoma
Kentaro Igarashi, Kei Kawaguchi, Ming Zhao, et al.
Anticancer Research
|
September 15, 2019
Oral Recombinant Methioninase, Combined With Oral Caffeine and Injected Cisplatinum, Overcome Cisplatinum-Resistance and Regresses Patient-derived Orthotopic Xenograft Model of Osteosarcoma
Takashi Higuchi, Hiromichi Oshiro, Kentaro Miyake, et al.
Cell Cycle (Georgetown, Tex.)
|
December 1, 2017
Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and prevention
Kei Kawaguchi, Qinghong Han, Shukuan Li, et al.
Oncotarget
|
March 16, 2018
Intra-tumor L-methionine level highly correlates with tumor size in both pancreatic cancer and melanoma patient-derived orthotopic xenograft (PDOX) nude-mouse models
Kei Kawaguchi, Qinghong Han, Shukuan Li, et al.
Anticancer Research
|
October 3, 2018
Oral Recombinant Methioninase Combined with Caffeine and Doxorubicin Induced Regression of a Doxorubicin-resistant Synovial Sarcoma in a PDOX Mouse Model
Takashi Higuchi, Kei Kawaguchi, Kentaro Miyake, et al.
Anticancer Research
|
September 15, 2019
Oral Recombinant Methioninase Overcomes Colorectal-cancer Liver Metastasis Resistance to the Combination of 5-Fluorouracil and Oxaliplatinum in a Patient-derived Orthotopic Xenograft Mouse Model
Hiromichi Oshiro, Yasunori Tome, Tasuku Kiyuna, et al.
Oncotarget
|
April 14, 2017
Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model
Takashi Murakami, Shukuan Li, Qinghong Han, et al.
Journal of Cellular Biochemistry
|
November 17, 2017
Growth of doxorubicin-resistant undifferentiated spindle-cell sarcoma PDOX is arrested by metabolic targeting with recombinant methioninase
Kentaro Igarashi, Shukuan Li, Qinghong Han, et al.
Chemotherapy
|
January 24, 2019
Combining Tumor-Selective Bacterial Therapy with Salmonella typhimurium A1-R and Cancer Metabolism Targeting with Oral Recombinant Methioninase Regressed an Ewing's Sarcoma in a Patient-Derived Orthotopic Xenograft Model
Kentaro Miyake, Tasuku Kiyuna, Shukuan Li, et al.
Oncotarget
|
May 4, 2018
Recombinant methioninase combined with doxorubicin (DOX) regresses a DOX-resistant synovial sarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model
Kentaro Igarashi, Kei Kawaguchi, Shukuan Li, et al.
Page
of 15